

TUCKER ELLIS & WEST LLP
MICHAEL C. ZELLERS - STATE BAR NO. 146904
DYLAN M. CARSON - STATE BAR NO. 237721
PETER E. SCHNAITMAN - STATE BAR NO. 218982
SARAH C. TRANKIEM - STATE BAR NO. 235031
515 South Flower Street, Suite 4200
Los Angeles, CA 90071-2223
Telephone: (213) 430-3400
Facsimile: (213) 430-3409

Attorneys for Defendants
MYLAN, INC., MYLAN
PHARMACEUTICALS, INC. and UDL
LABORATORIES, INC.

**UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA**

Defendants Mylan, Inc. (“Mylan”), Mylan Pharmaceuticals, Inc. (“Mylan Pharmaceuticals”), and UDL Laboratories, Inc. (“UDL Laboratories”) (hereinafter collectively referred to as “Defendants”) submit this Answer to Plaintiffs’ Complaint.

I. INTRODUCTION

1. Defendants deny the allegations in paragraph 1 of Plaintiffs' Complaint.
2. Defendants admit that Digitek® is indicated for the treatment of heart failure and abnormal heart rhythms. Defendants admit that at all times relevant to the captioned matter, Actavis Totowa manufactured Digitek® pursuant to an Abbreviated New Drug Application

1 ("ANDA"), Mylan Pharmaceuticals distributed Digitek® under a "Bertek" label and UDL
 2 Laboratories distributed Digitek® under a "UDL" label. Defendants deny the remaining
 3 allegations in paragraph 2 of Plaintiffs' Complaint.

4 3. Defendants admit that Digitek® was marketed as a safe and effective medication.
 5 Defendants deny the remaining allegations in paragraph 3 of Plaintiffs' Complaint, specifically
 6 denying that any Digitek® tablets used by decedent William Davis ("Decedent") were defective.

7 4. Defendants admit that on April 25, 2008, Actavis Totowa initiated a voluntary
 8 nationwide recall of all lots of Digitek®. Defendants deny for want of knowledge, lack of
 9 information, and because they are not true the remaining allegations in paragraph 4 of Plaintiffs'
 10 Complaint, specifically denying that any Digitek® tablets used by Decedent were defective and
 11 that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs'
 12 Complaint.

13 **II. JURISDICTION AND VENUE**

14 5. Defendants lack sufficient knowledge or information so as to form a belief as to
 15 the truth of the allegations in paragraph 5 of Plaintiffs' Complaint.

16 6. Defendants lack sufficient knowledge or information so as to form a belief as to
 17 the truth of the allegations in paragraph 6 of Plaintiffs' Complaint.

18 **III. PARTIES**

19 7. Defendants lack sufficient knowledge or information so as to form a belief as to
 20 the truth of the allegations in paragraph 7 of Plaintiffs' Complaint, and therefore deny the same.

21 8. Defendants lack sufficient knowledge or information so as to form a belief as to
 22 the truth of the allegations in paragraph 8 of Plaintiffs' Complaint, and therefore deny the same.

23 9. Defendants lack sufficient knowledge or information so as to form a belief as to
 24 the truth of the allegations in paragraph 9 of Plaintiffs' Complaint, and therefore deny the same.

25 10. Defendants admit that Actavis Group is an Icelandic corporation with its principal
 26 place of business in Iceland. Defendants deny the remaining allegations in paragraph 10,
 27 specifically denying that Actavis Group had any involvement in the activities regarding
 28 Digitek® as alleged in paragraph 10 of Plaintiffs' Complaint.

1 11. Defendants admit that Actavis Totowa, LLC is a Delaware limited liability
 2 company with its principal place of business in New Jersey. Defendants deny the remaining
 3 allegations in paragraph 11 of Plaintiffs' Complaint.

4 12. Defendants admit that Mylan Inc. is a Pennsylvania corporation with its principal
 5 place of business in Pennsylvania. Defendants deny the remaining allegations in paragraph 12 of
 6 Plaintiffs' Complaint.

7 13. Defendants admit that Mylan Pharmaceuticals, Inc. is a West Virginia corporation
 8 with its principal place of business in West Virginia. Defendants deny the remaining allegations
 9 in paragraph 13 of Plaintiffs' Complaint.

10 14. Defendants admit that UDL Laboratories, Inc. is an Illinois corporation with its
 11 principal place of business in Illinois. Defendants deny the remaining allegations in paragraph
 12 14 of Plaintiffs' Complaint.

13 15. Defendants admit that at all times relevant to the captioned matter, Actavis
 14 Totowa manufactured Digitek® pursuant to an ANDA, Mylan Pharmaceuticals distributed
 15 Digitek® under a "Bertek" label and UDL Laboratories, Inc. distributed Digitek® under a
 16 "UDL" label. Defendants deny the remaining allegations in paragraph 15 of Plaintiffs'
 17 Complaint, specifically denying that Digitek® was the proximate cause of the injuries and
 18 damages alleged in Plaintiffs' Complaint.

19 16. Defendants deny the allegations in paragraph 16 of Plaintiffs' Complaint,
 20 specifically denying that any breach of duty occurred.

21 17. Defendants admit that at all times relevant to the captioned matter, Actavis
 22 Totowa manufactured Digitek® pursuant to an ANDA, Mylan Pharmaceuticals distributed
 23 Digitek® under a "Bertek" label and UDL Laboratories, Inc. distributed Digitek® under a
 24 "UDL" label. Defendants deny the remaining allegations in paragraph 17 of Plaintiffs'
 25 Complaint.

26 18. Defendants deny the allegations in paragraph 18 of Plaintiffs' Complaint.

1 **IV. FACTUAL BASIS FOR THE CLAIMS ASSERTED**

2 19. Defendants admit that Digitek® is a cardiac glycoside indicated for the treatment
 3 of heart failure and abnormal heart rhythms. Defendants deny the remaining allegations in
 4 paragraph 19 of Plaintiffs' Complaint.

5 20. Defendants admit that Digitek® is indicated for the treatment of heart failure and
 6 abnormal heart rhythms. Defendants deny the remaining allegations in paragraph 20 of
 7 Plaintiffs' Complaint.

8 21. Defendants deny for want of knowledge, lack of information, and because they
 9 are not true the allegations in paragraph 21 of Plaintiffs' Complaint.

10 22. Defendants admit that digoxin overdose and digitalis toxicity can cause serious
 11 injury and even death. Defendants deny the remaining allegations in paragraph 22 of Plaintiffs'
 12 Complaint, specifically denying that Decedent exhibited such symptoms or conditions as a result
 13 of his alleged use of Digitek®.

14 23. Defendants admit that at all times relevant to the captioned matter, Actavis
 15 Totowa manufactured Digitek® pursuant to an ANDA.

16 24. Defendants admit that at all times relevant to the captioned matter, Mylan
 17 Pharmaceuticals distributed Digitek® under a "Bertek" label and UDL Laboratories Inc.
 18 distributed Digitek® under a "UDL" label.

19 25. Defendants admit that the Food and Drug Administration ("FDA") approved the
 20 sale of 0.125 mg and 0.250 mg dosages of Digitek®, but deny the remaining allegations in
 21 paragraph 25 of Plaintiffs' Complaint.

22 26. Defendants admit that the FDA approved the sale of 0.125 mg and 0.250 mg
 23 dosages of Digitek®, but deny the remaining allegations in paragraph 26 of Plaintiffs'
 24 Complaint.

25 27. Defendants admit that on April 25, 2008, Actavis Totowa initiated a voluntary
 26 nationwide recall of all lots of Digitek®. Defendants deny the remaining allegations in
 27 paragraph 27 of Plaintiffs' Complaint, specifically denying that any Digitek® tablets used by
 28 Decedent were defective.

1 28. Defendants deny the allegations in paragraph 28 of Plaintiffs' Complaint.
 2 29. Defendants admit that the FDA has issued "Good Manufacturing Practice"
 3 guidelines. The guidelines speak for themselves and, on that basis, Defendants deny the
 4 remaining allegations in paragraph 29 of Plaintiffs' Complaint.

5 30. Defendants deny the allegations in paragraph 30 of Plaintiffs' Complaint.
 6 31. Defendants admit that at all times relevant to the captioned matter, Actavis
 7 Totowa manufactured Digitek® pursuant to an ANDA, but deny the remaining allegations in
 8 paragraph 31 of Plaintiffs' Complaint.

9 32. Defendants admit that the FDA issued a letter to Actavis Totowa on August 15,
 10 2006. The letter speaks for itself. Defendants deny the remaining allegations in paragraph 32 of
 11 Plaintiffs' Complaint.

12 33. Defendants admit that the FDA issued a letter to Actavis Totowa on August 15,
 13 2006. The letter speaks for itself. Defendants deny the remaining allegations in paragraph 33 of
 14 Plaintiffs' Complaint.

15 34. Defendants admit that the FDA issued a letter to Actavis Totowa on August 15,
 16 2006. The letter speaks for itself. Defendants deny the remaining allegations in paragraph 34 of
 17 Plaintiffs' Complaint.

18 35. Defendants admit that the FDA issued a letter to Actavis Totowa on February 1,
 19 2007. The letter speaks for itself. Defendants deny the remaining allegations in paragraph 35 of
 20 Plaintiffs' Complaint.

21 36. Defendants admit that the FDA issued a letter to Actavis Totowa on February 1,
 22 2007. The letter speaks for itself. Defendants deny the remaining allegations in paragraph 36 of
 23 Plaintiffs' Complaint.

24 37. Defendants admit that Actavis Totowa issued a press release concerning the
 25 voluntary nationwide recall of Digitek® on April 25, 2008. The press release speaks for itself.
 26 Defendants deny the remaining allegations in paragraph 37 of Plaintiffs' Complaint.

27 38. Defendants deny the allegations in paragraph 38 of Plaintiffs' Complaint.
 28

39. Defendants deny the allegations in paragraph 39 of Plaintiffs' Complaint, specifically denying that any Digitek® tablets used by Decedent were defective and that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

V. CAUSES OF ACTION

FIRST CAUSE OF ACTION

Breach of Express Warranty

40. In response to paragraph 40 of Plaintiff's Complaint, Defendants reallege and incorporate by reference their answers to paragraphs 1 – 39 of Plaintiff's Complaint, as if fully set forth herein.

41. Defendants deny the allegations in paragraph 41 of Plaintiffs' Complaint, specifically denying the existence of any warranties in favor of, or representations to, Decedent and/or Plaintiffs by Defendants regarding Digitek®.

42. Defendants deny the allegations in paragraph 42 of Plaintiffs' Complaint, specifically denying the existence of any warranties in favor of, or representations to, Decedent and/or Plaintiffs by Defendants regarding Digitek® and that Decedent exhibited such symptoms or conditions as a result of his alleged use of Digitek®.

43. Defendants deny the allegations in paragraph 43 of Plaintiffs' Complaint, specifically denying the existence of any warranties in favor of, or representations to, Decedent and/or Plaintiffs by Defendants regarding Digitek®, that any Digitek® tablets used by Decedent were defective, and that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

44. Defendants deny the allegations in paragraph 44 of Plaintiffs' Complaint, specifically denying the existence of any warranties in favor of, or representations to, Decedent and/or Plaintiffs by Defendants regarding Digitek®, that any Digitek® tablets used by Decedent were defective, and that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

45. Defendants deny the allegations in paragraph 45 of Plaintiffs' Complaint, specifically denying that Digitek® was the proximate cause of the injuries and damages alleged

1 in Plaintiffs' Complaint.

2 46. Defendants deny the allegations in paragraph 46 of Plaintiffs' Complaint,
 3 specifically denying that Digitek® was the proximate cause of the injuries and damages alleged
 4 in Plaintiffs' Complaint.

5 47. Defendants deny the allegations in paragraph 47 of Plaintiffs' Complaint,
 6 specifically denying that Digitek® was the proximate cause of the injuries and damages alleged
 7 in Plaintiffs' Complaint.

8 **SECOND CAUSE OF ACTION**

9 **Breach of Implied Warranty**

10 48. In response to paragraph 48 of Plaintiff's Complaint, Defendants reallege and
 11 incorporate by reference their answers to paragraphs 1 – 47 of Plaintiff's Complaint, as if fully
 12 set forth herein.

13 49. Defendants admit that at all times relevant to this lawsuit, Digitek® was safe and
 14 effective when used in accordance with its FDA-approved prescribing information. Defendants
 15 deny the remaining allegations in paragraph 49 of Plaintiffs' Complaint, specifically denying the
 16 existence of any warranties in favor of, or representations to, Decedent and/or Plaintiffs
 17 regarding Digitek®.

18 50. Defendants deny the allegations in paragraph 50 of Plaintiffs' Complaint.

19 51. Defendants deny the allegations contained in paragraph 51 of Plaintiffs'
 20 Complaint, specifically denying the existence of any warranties in favor of, or representations to,
 21 Decedent and/or Plaintiffs regarding Digitek®.

22 52. The allegations in paragraph 52 state legal conclusions to which no response is
 23 required. To the extent a response is required, Defendants deny the allegations in paragraph 52
 24 of Plaintiffs' Complaint, specifically denying that Digitek® was the proximate cause of the
 25 injuries and damages alleged in Plaintiffs' Complaint.

26 53. Defendants deny the allegations in paragraph 53 of Plaintiffs' Complaint,
 27 specifically denying that Digitek® was the proximate cause of the injuries and damages alleged
 28 in Plaintiffs' Complaint.

54. Defendants deny the allegations in paragraph 54 of Plaintiffs' Complaint, specifically denying that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

55. Defendants deny the allegations in paragraph 55 of Plaintiffs' Complaint, specifically denying that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

THIRD CAUSE OF ACTION

Strict Product Liability - Failure to Warn

56. In response to paragraph 56 of Plaintiff's Complaint, Defendants reallege and incorporate by reference their answers to paragraphs 1 – 55 of Plaintiff's Complaint, as if fully set forth herein.

57. Defendants admit that at all times relevant to the captioned matter, Actavis Totowa manufactured Digitek® pursuant to an ANDA, Mylan Pharmaceuticals distributed Digitek® under a “Bertek” label and UDL Laboratories distributed Digitek® under a “UDL” label. Defendants deny the remaining allegations in paragraph 57 of Plaintiffs’ Complaint.

58. Defendants deny the allegations in paragraph 58 of Plaintiffs' Complaint, specifically denying that any Digitek® tablets used by Decedent were defective and that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

59. Defendants deny for want of knowledge, lack of information, and because they are not true the allegations in paragraph 59 of Plaintiffs' Complaint, specifically denying that any Digitek® tablets used by Decedent were defective and that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

60. Defendants deny for want of knowledge, lack of information, and because they are not true the allegations in paragraph 60 of Plaintiffs' Complaint.

61. Defendants deny the allegations in paragraph 61 of Plaintiffs' Complaint, specifically denying that any Digitek® tablets used by Decedent were defective and that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

62. Defendants deny the allegations in paragraph 62 of Plaintiffs' Complaint, specifically denying that any Digitek® tablets used by Decedent were defective and that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

63. Defendants deny the allegations in paragraph 63 of Plaintiffs' Complaint, specifically denying that any Digitek® tablets used by Decedent were defective and that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

64. Defendants deny the allegations in paragraph 64 of Plaintiffs' Complaint, specifically denying that any Digitek® tablets used by Decedent were defective and that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

65. Defendants deny the allegations in paragraph 65 of Plaintiffs' Complaint, specifically denying that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

66. Defendants deny the allegations in paragraph 66 of Plaintiffs' Complaint, specifically denying that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

67. Defendants deny the allegations in paragraph 67 of Plaintiffs' Complaint, specifically denying that any Digitek® tablets used by Decedent were defective and that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

FOURTH CAUSE OF ACTION

Strict Product Liability – Manufacturing Defect

68. In response to paragraph 68 of Plaintiff's Complaint, Defendants reallege and incorporate by reference their answers to paragraphs 1 – 67 of Plaintiff's Complaint, as if fully set forth herein.

69. Defendants admit that at all times relevant to the captioned matter, Actavis Totowa manufactured Digitek® pursuant to an ANDA, Mylan Pharmaceuticals distributed Digitek® under a “Bertek” label and UDL Laboratories distributed Digitek® under a “UDL” label. Defendants deny the remaining allegations in paragraph 69 of Plaintiffs’ Complaint.

70. Defendants admit that Digitek® tablets were expected to reach patients without a substantial change in their condition from the time they were sold. Defendants deny the remaining allegations in paragraph 70 of Plaintiffs' Complaint.

71. Defendants deny the allegations in paragraph 71 of Plaintiffs' Complaint, specifically denying that any Digitek® tablets used by Decedent were defective.

72. Defendants deny the allegations in paragraph 72 of Plaintiffs' Complaint, specifically denying that any Digitek® tablets used by Decedent were defective.

73. Defendants deny the allegations in paragraph 73 of Plaintiffs' Complaint, specifically denying that any Digitek® tablets used by Decedent were defective and that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

74. Defendants deny the allegations in paragraph 74 of Plaintiffs' Complaint, specifically denying that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

75. Defendants deny the allegations in paragraph 75 of Plaintiffs' Complaint, specifically denying that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

76. Defendants deny the allegations in paragraph 76 of Plaintiffs' Complaint, specifically denying that any Digitek® tablets used by Decedent were defective and that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

FIFTH CAUSE OF ACTION

Fraud and Deceit

77. In response to paragraph 77 of Plaintiff's Complaint, Defendants reallege and incorporate by reference their answers to paragraphs 1 – 76 of Plaintiff's Complaint, as if fully set forth herein.

78. Defendants deny the allegations in paragraph 78 of Plaintiffs' Complaint, specifically denying the existence of any representations to Decedent and/or Plaintiffs by Defendants and that any Digitek® tablets used by Decedent were defective.

1 79. Defendants deny the allegations in paragraph 79 of Plaintiffs' Complaint,
 2 specifically denying the existence of any representations to Decedent and/or Plaintiffs by
 3 Defendants and that any Digitek® tablets used by Decedent were defective.

4 80. Defendants deny the allegations in paragraph 80 of Plaintiffs' Complaint,
 5 specifically denying the existence of any representations to Decedent and/or Plaintiffs by
 6 Defendants and that any Digitek® tablets used by Decedent were defective.

7 81. Defendants deny the allegations in paragraph 81 of Plaintiffs' Complaint,
 8 specifically denying the existence of any representations to Decedent and/or Plaintiffs by
 9 Defendants and that any Digitek® tablets used by Decedent were defective.

10 82. Defendants deny the allegations in paragraph 82 of Plaintiffs' Complaint,
 11 specifically denying the existence of any representations to Decedent and/or Plaintiffs by
 12 Defendants, that any Digitek® tablets used by Decedent were defective, and that Digitek® was
 13 the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

14 83. Defendants admit that at all times relevant to the captioned matter, Actavis
 15 Totowa manufactured Digitek® pursuant to an ANDA, Mylan Pharmaceuticals distributed
 16 Digitek® under a "Bertek" label and UDL Laboratories distributed Digitek® under a "UDL"
 17 label. Defendants deny the remaining allegations in paragraph 83 of Plaintiffs' Complaint,
 18 specifically denying the existence of any representations to Decedent and/or Plaintiffs by
 19 Defendants.

20 84. Defendants deny the allegations in paragraph 84 of Plaintiffs' Complaint,
 21 specifically denying the existence of any representations to Decedent and/or Plaintiffs by
 22 Defendants.

23 85. Defendants deny the allegations in paragraph 85 of Plaintiffs' Complaint.

24 86. Defendants deny the allegations in paragraph 86 of Plaintiffs' Complaint,
 25 specifically denying that any Digitek® tablets used by Decedent were defective and that
 26 Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

27 87. Defendants deny the allegations in paragraph 87 of Plaintiffs' Complaint,
 28 specifically denying that Digitek® was the proximate cause of the injuries and damages alleged

1 in Plaintiffs' Complaint.

2 88. Defendants deny the allegations in paragraph 88 of Plaintiffs' Complaint,
 3 specifically denying that Digitek® was the proximate cause of the injuries and damages alleged
 4 in Plaintiffs' Complaint.

5 89. Defendants deny the allegations in paragraph 89 of Plaintiffs' Complaint,
 6 specifically denying that any Digitek® tablets used by Decedent were defective and that
 7 Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

8 **SIXTH CAUSE OF ACTION**

9 **Negligent Misrepresentation**

10 90. In response to paragraph 90 of Plaintiff's Complaint, Defendants reallege and
 11 incorporate by reference their answers to paragraphs 1 – 89 of Plaintiff's Complaint, as if fully
 12 set forth herein.

13 91. Defendants admit that at all times relevant to this lawsuit, Digitek® was safe and
 14 effective when used in accordance with its FDA-approved prescribing information. Defendants
 15 deny the remaining allegations in paragraph 91 of Plaintiffs' Complaint, specifically denying the
 16 existence of any representations to Decedent and/or Plaintiffs regarding Digitek®.

17 92. Defendants deny the allegations in paragraph 92 of Plaintiffs' Complaint,
 18 specifically denying the existence of any representations to Decedent and/or Plaintiffs by
 19 Defendants and that any Digitek® tablets used by Decedent were defective.

20 93. Defendants deny the allegations in paragraph 93 of Plaintiffs' Complaint,
 21 specifically denying the existence of any representations to Decedent and/or Plaintiffs by
 22 Defendants and that any Digitek® tablets used by Decedent were defective.

23 94. Defendants deny the allegations in paragraph 94 of Plaintiffs' Complaint,
 24 specifically denying the existence of any representations to Decedent and/or Plaintiffs by
 25 Defendants and that any Digitek® tablets used by Decedent were defective.

26 95. Defendants deny the allegations in paragraph 95 of Plaintiffs' Complaint,
 27 specifically denying the existence of any representations to Decedent and/or Plaintiffs by

28

1 Defendants, that any Digitek® tablets used by Decedent were defective and that Digitek® was
 2 the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

3 96. Defendants deny the allegations in paragraph 96 of Plaintiffs' Complaint,
 4 specifically denying that Digitek® was the proximate cause of the injuries and damages alleged
 5 in Plaintiffs' Complaint.

6 97. Defendants deny the allegations in paragraph 97 of Plaintiffs' Complaint,
 7 specifically denying that Digitek® was the proximate cause of the injuries and damages alleged
 8 in Plaintiffs' Complaint.

9 98. Defendants deny the allegations in paragraph 98 of Plaintiffs' Complaint,
 10 specifically denying that Digitek® was the proximate cause of the injuries and damages alleged
 11 in Plaintiffs' Complaint.

12 99. Defendants deny the allegations in paragraph 99 of Plaintiffs' Complaint,
 13 specifically denying that any Digitek® tablets used by Decedent were defective and that
 14 Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

15 **SEVENTH CAUSE OF ACTION**

16 **Negligence and Negligence Per Se**

17 100. In response to paragraph 100 of Plaintiff's Complaint, Defendants reallege and
 18 incorporate by reference their answers to paragraphs 1 – 99 of Plaintiff's Complaint, as if fully
 19 set forth herein.

20 101. Defendants admit that Actavis Totowa, Mylan Pharmaceuticals, and UDL
 21 Laboratories were subject only to those duties imposed by applicable law and deny that any such
 22 duty was breached. Defendants deny the remaining allegations in paragraph 101 of Plaintiffs'
 23 Complaint.

24 102. Defendants deny the allegations in paragraph 102 of Plaintiffs' Complaint,
 25 specifically denying that any Digitek® tablets used by Decedent were defective.

26 103. Defendants deny the allegations in paragraph 103 of Plaintiffs' Complaint,
 27 specifically denying that any Digitek® tablets used by Decedent were defective and that
 28 Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

104. Defendants deny the allegations in paragraph 104 of Plaintiffs' Complaint, specifically denying that any Digitek® tablets used by Decedent were defective.

105. Defendants deny the allegations in paragraph 105 of Plaintiffs' Complaint, specifically denying that any Digitek® tablets used by Decedent were defective and that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

106. Defendants deny the allegations in paragraph 106 of Plaintiffs' Complaint.

107. The allegations in paragraph 107 state legal conclusions to which no response is required. To the extent a response is required, Defendants deny the allegations in paragraph 107 of Plaintiffs' Complaint.

108. Defendants deny the allegations in paragraph 108 of Plaintiffs' Complaint, specifically denying that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

109. Defendants deny the allegations in paragraph 109 of Plaintiffs' Complaint, specifically denying that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

110. Defendants deny the allegations in paragraph 110 of Plaintiffs' Complaint, specifically denying that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

111. Defendants deny the allegations in paragraph 111 of Plaintiffs' Complaint, specifically denying that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

EIGHTH CAUSE OF ACTION

Negligent Infliction of Emotional Distress On Behalf of Dephlia Davis Only

112. In response to paragraph 112 of Plaintiff's Complaint, Defendants reallege and incorporate by reference their answers to paragraphs 1 – 111 of Plaintiff's Complaint, as if fully set forth herein.

113. Defendants lack sufficient knowledge or information so as to form a belief as to the truth of the allegations in paragraph 113 of Plaintiffs' Complaint, and therefore deny the same.

114. Defendants deny the allegations in paragraph 114 of Plaintiffs' Complaint, specifically denying that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

115. Defendants deny the allegations in paragraph 115 of Plaintiffs' Complaint, specifically denying that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

116. Defendants deny the allegations in paragraph 116 of Plaintiffs' Complaint, specifically denying that Digitek® was the proximate cause of the injuries and damages alleged in Plaintiffs' Complaint.

PRAAYER FOR RELIEF

Defendants deny that Plaintiffs are entitled to any recovery of damages contained in Plaintiffs' unnumbered Prayer for Relief.

AFFIRMATIVE DEFENSES

FIRST AFFIRMATIVE DEFENSE

Plaintiffs' Complaint fails to state facts sufficient to constitute a cause of action against these Defendants.

SECOND AFFIRMATIVE DEFENSE

This Court lacks personal jurisdiction over these Defendants.

THIRD AFFIRMATIVE DEFENSE

Plaintiffs are barred from any recovery against these Defendants by the doctrines of waiver and estoppel.

FOURTH AFFIRMATIVE DEFENSE

The Complaint is barred by reason of the doctrine of laches and by the fundamental unfairness and prejudice of the excessive and lengthy delay from the date of the alleged use of the subject pharmaceutical products to the filing of the Complaint.

FIFTH AFFIRMATIVE DEFENSE

Defendants state on information and belief that the Complaint and each purported cause of action contained therein is barred by the statutes of limitation contained in California Code of Civil Procedure §§ 335.1 and 338 and former section 340(3), and such other statutes of limitation as may apply.

SIXTH AFFIRMATIVE DEFENSE

Any and all injuries suffered by Plaintiffs, the fact of which is expressly denied by these Defendants, were the direct and proximate result of sensitivities, medical conditions, reactions and/or idiosyncrasies peculiar to Decedent that were unknown, unknowable or not reasonably foreseeable to these Defendants, and not, as alleged, as a direct and proximate result of wrongful conduct on the part of these Defendants, the fact of which is expressly denied by these Defendants.

SEVENTH AFFIRMATIVE DEFENSE

No act or omission of these answering Defendants was a substantial factor in bringing about the alleged injuries of Decedent and/or Plaintiffs, nor was any such act or omission a contributing cause thereof, and any alleged acts or omissions of these Defendants were superseded by the acts or omissions of others, including Decedent and/or Plaintiffs, which were the independent, intervening and proximate cause of any injury, damage, or loss sustained by Plaintiffs.

EIGHTH AFFIRMATIVE DEFENSE

Defendants state on information and belief that any injuries, losses or damages suffered by Decedent and/or Plaintiffs were proximately caused, in whole or in part, by the failure of Decedent to exercise ordinary care and to follow the advice, information, warnings and/or instructions provided with the products and therefore, Plaintiffs' recovery, if any, must be diminished by the proportion of the negligence of Decedent which proximately caused or contributed to the alleged injuries, losses or damages.

NINTH AFFIRMATIVE DEFENSE

Defendants state on information and belief that any injuries, losses or damages suffered by the Decedent and/or Plaintiffs were proximately caused, in whole or in part, by the negligence or other actionable conduct of persons or entities other than these Defendants. Therefore, Plaintiffs' recovery against these Defendants, if any, should be reduced pursuant to California Civil Code § 1431.2.

TENTH AFFIRMATIVE DEFENSE

Defendants state on information and belief that Decedent and/or Plaintiffs failed to mitigate their injuries, losses or damages, if any, suffered as a result of the incident and facts set forth in the Complaint.

ELEVENTH AFFIRMATIVE DEFENSE

Plaintiffs' alleged injuries and damages, if any, were the result of the misuse of the subject pharmaceutical products at issue. Defendants further allege that if Plaintiffs suffered injuries attributable to the use of the subject pharmaceutical products at issue in this suit, which allegations are expressly denied, the injuries, if any, were solely caused and attributable to the unreasonable, unforeseeable and improper use of said pharmaceutical products by Decedent and/or third parties.

TWELFTH AFFIRMATIVE DEFENSE

Plaintiffs have failed to join all indispensable parties; as a result of such failure to join, complete relief cannot be accorded to those already parties to the action and will result in prejudice to these Defendants in any possible future litigation.

THIRTEENTH AFFIRMATIVE DEFENSE

The manufacture, distribution and sale of the pharmaceutical products referred to in Plaintiffs' Complaint were at all times in compliance with all federal regulations and statutes, and Plaintiffs' causes of action are preempted.

FOURTEENTH AFFIRMATIVE DEFENSE

To the extent that Plaintiffs assert claims based on these Defendants' alleged adherence or lack of adherence to and compliance with applicable federal laws, regulations, and rules, such claims are preempted by federal law under the Supremacy Clause of the United States Constitution.

FIFTEENTH AFFIRMATIVE DEFENSE

Plaintiffs are barred from recovering against Defendants because Plaintiffs' claims are preempted in accordance with the Supremacy Clause of the United States Constitution and by the Federal Food, Drug and Cosmetics Act, 21 U.S.C. § 301 et. seq., and regulations promulgated thereunder, with the regulations promulgated by the Food and Drug Administration to implement the FDCA, with the purposes and objectives of the FDCA and the Food and Drug Administration's implementing regulations, and with the specific determinations by the Food and Drug Administration specifying the language that should be used in the labeling accompanying the subject pharmaceutical products.

SIXTEENTH AFFIRMATIVE DEFENSE

Plaintiffs' claims are barred in whole or in part under the applicable state law because the subject pharmaceutical products at issue were subject to and received pre-market approval by the Food and Drug Administration under 52 Stat. 1040, 21 U.S.C. § 301.

SEVENTEENTH AFFIRMATIVE DEFENSE

Plaintiffs' claims are barred in whole or in part by the deference given to the primary jurisdiction of the Food and Drug Administration over the subject pharmaceutical products at issue under applicable federal laws, regulations, and rules.

EIGHTEENTH AFFIRMATIVE DEFENSE

Plaintiffs' claims are barred in whole or in part because there is no private right of action concerning matters regulated by the Food and Drug Administration under applicable federal laws, regulations, and rules.

NINETEENTH AFFIRMATIVE DEFENSE

The warning, labeling, advertising and sale of the subject pharmaceutical products at issue complied at all times with the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 300 et seq. and the Federal Trade Commission Act, 15 U.S.C. § 41 et seq. Consequently, Plaintiffs' Complaint is preempted by these acts and compliance with these acts constitutes a complete or partial defense to the allegations of Plaintiffs' Complaint against Defendants, including any claim for punitive damages. Alternatively, Defendants are entitled to a presumption that the subject pharmaceutical products at issue are not defective or unreasonably dangerous and that their labeling was adequate.

TWENTIETH AFFIRMATIVE DEFENSE

If any pharmaceutical products distributed by these Defendants were involved in the incident alleged in the Complaint herein, which these Defendants deny, then and in that event,

1 said pharmaceutical products were not defective at the time that they left the control of these
 2 Defendants.

3

4 **TWENTY-FIRST AFFIRMATIVE DEFENSE**

5 California's judicially-created definitions of manufacturing defect and design defect, and
 6 standards for determining whether there has been an actionable failure to warn, are
 7 unconstitutional in that, among other things, they are void for vagueness and an undue burden on
 8 interstate commerce, as well as an impermissible effort to regulate in an area that previously has
 9 been preempted by the federal government.

10

11 **TWENTY-SECOND AFFIRMATIVE DEFENSE**

12 The subject pharmaceutical products alleged in Plaintiffs' Complaint conformed to the
 13 then current state of the art. Further, the then current state of medical, scientific and industrial
 14 knowledge, art and practice was such that these Defendants did not know, and could not
 15 reasonably have known, that the subject pharmaceutical products might pose a risk of harm in
 16 normal and foreseeable use.

17

18 **TWENTY-THIRD AFFIRMATIVE DEFENSE**

19 Defendants allege that the pharmaceutical products at issue were fit and proper for their
 20 intended purpose and that the utility of the subject pharmaceutical products at issue outweigh any
 21 possible risk inherent in the use of the subject pharmaceutical products.

22

23 **TWENTY-FOURTH AFFIRMATIVE DEFENSE**

24 Defendants are informed and believe and thereon allege that, at or about the times, dates
 25 and places mentioned in the Complaint, if any risk was attendant upon Plaintiffs, which
 26 Defendants deny, Plaintiffs knew full well of such risk, were warned of such risk and voluntarily,
 27 and without compulsion or coercion, encountered and assumed such risk.

28

TWENTY-FIFTH AFFIRMATIVE DEFENSE

The subject pharmaceutical products at issue have at all relevant times been available only upon the prescription of a licensed physician, and Decedent's prescribing physicians stood in the position of the learned intermediaries between Defendants and Plaintiffs. To the extent that Plaintiffs assert claims based on an alleged failure by Defendants to warn directly of alleged dangers associated with the use of the subject pharmaceutical products at issue, such claims are barred because Defendants have discharged their duty to warn in the warnings given to the prescribing physicians, under the learned intermediary doctrine.

TWENTY-SIXTH AFFIRMATIVE DEFENSE

Plaintiffs' claims against Defendants are barred under § 6(c) of the Restatement of Torts (Third): Products Liability.

TWENTY-SEVENTH AFFIRMATIVE DEFENSE

Plaintiffs' strict liability claims are barred by the unavoidably dangerous product defense stated in Comment k to § 402A of the Restatement (Second) of Torts.

TWENTY-EIGHTH AFFIRMATIVE DEFENSE

Plaintiffs' claims are barred in whole or in part because Defendants provided adequate "direction or warnings" as to the use of the subject pharmaceutical products at issue within the meaning of Comment j to § 402A of the Restatement (Second) of Torts.

TWENTY-NINTH AFFIRMATIVE DEFENSE

Plaintiffs' claims are barred in whole or in part because the subject pharmaceutical products at issue "provide net benefits for a class of patients" within the meaning of Comment f to § 6 of the Restatement (Third) of Torts: Products Liability.

THIRTIETH AFFIRMATIVE DEFENSE

Plaintiffs' claims are barred under § 4, et seq., of the Restatement (Third) of Torts: Products Liability.

THIRTY-FIRST AFFIRMATIVE DEFENSE

Defendants allege that in the event that reliance was placed upon Defendants' nonconformance to an express representation, this action is barred since there was no reliance upon representations, if any, of these Defendants.

THIRTY-SECOND AFFIRMATIVE DEFENSE

Plaintiffs' claims of fraud and concealment are barred by reason of Plaintiffs' failure to allege the circumstances constituting the alleged fraud and concealment with particularity.

THIRTY-THIRD AFFIRMATIVE DEFENSE

Defendants are informed and believe and thereon allege that Plaintiffs failed to provide Defendants with timely notice of any alleged nonconformance with any express representation.

THIRTY-FOURTH AFFIRMATIVE DEFENSE

To the extent that Plaintiffs seek punitive damages for the conduct which allegedly caused injuries asserted in the Complaint, punitive damages are barred or reduced by applicable law or statute or, in the alternative, are unconstitutional insofar as they violate the due process protections afforded by the United States Constitution, the excessive fines clause of the Eighth Amendment of the United States Constitution, the Commerce Clause of the United States Constitution, the Full Faith and Credit Clause of the United States Constitution, and applicable provisions of the Constitution of the State of California. Any law, statute, or other authority purporting to permit the recovery of punitive damages in this case is unconstitutional, facially and as applied, to the extent that, without limitation, it: (1) lacks constitutionally sufficient standards to guide and restrain the jury's discretion in determining whether to award punitive

1 damages and/or the amount, if any; (2) is void for vagueness in that it failed to provide adequate
 2 advance notice as to what conduct will result in punitive damages; (3) permits recovery of
 3 punitive damages based on out-of state conduct, conduct that complied with applicable law, or
 4 conduct that was not directed, or did not proximately cause harm, to Plaintiffs; (4) permits
 5 recovery of punitive damages in an amount that is not both reasonable and proportionate to the
 6 amount of harm, if any, to Plaintiffs and to the amount of compensatory damages; if any; (5)
 7 permits jury consideration of net worth or other financial information relating to these
 8 Defendants; (6) lacks constitutionally sufficient standards to be applied by the trial court in post-
 9 verdict review of any punitive damages awards; (7) lacks constitutionally sufficient standards for
 10 appellate review of punitive damages awards; and (8) otherwise fails to satisfy Supreme Court
 11 precedent.

12

13

THIRTY-FIFTH AFFIRMATIVE DEFENSE

14 To the extent that Plaintiffs seek punitive damages for an alleged act or omission of these
 15 Defendants, no act or omission was oppressive, fraudulent, or malicious, under California Civil
 16 Code § 3294, and therefore, any award of punitive damages is barred. Any claim for punitive
 17 damages is also barred under California Civil Code § 3294(b).

18

19

THIRTY-SIXTH AFFIRMATIVE DEFENSE

20 Plaintiffs' claims are barred in whole or in part because all acts or omissions by these
 21 Defendants (or their agents or representatives) were privileged or justified and any claim based
 22 thereon is barred.

23

24

THIRTY-SEVENTH AFFIRMATIVE DEFENSE

25 Plaintiffs' claims are barred in whole or in part because Plaintiffs lack standing to bring
 26 such claims.

27

28

THIRTY-EIGHTH AFFIRMATIVE DEFENSE

Plaintiffs' claims are barred in whole or in part because Defendants have been improperly joined in this action.

THIRTY-NINTH AFFIRMATIVE DEFENSE

Defendant and/or Plaintiffs were contributorily or comparatively negligent, which contributory or comparative negligence constitutes a proximate cause of harm to them.

FORTIETH AFFIRMATIVE DEFENSE

Plaintiffs' claims are barred because Decedent would have taken the subject pharmaceutical products even if the subject pharmaceutical products' labeling contained the information that Plaintiffs contend should have been provided.

FORTY-FIRST AFFIRMATIVE DEFENSE

Plaintiffs' claims are barred, in whole or in part, because the advertisements, if any, and labeling with respect to the subject pharmaceutical products were not false or misleading and, therefore, constitute protected commercial speech under the applicable provisions of the United States Constitution.

FORTY-SECOND AFFIRMATIVE DEFENSE

Plaintiffs' claims are barred, in whole or in part, by the doctrine of accord and satisfaction.

FORTY-THIRD AFFIRMATIVE DEFENSE

Defendants are entitled to credit for any settlement of claims for alleged injuries and damages made by Plaintiffs with any other defendant or other person or entity.

FORTY-FOURTH AFFIRMATIVE DEFENSE

2 To the extent that Plaintiffs' claims are based on a theory providing for liability without
 3 proof of causation, the claims violate Defendants' rights under the United States Constitution.

FORTY-FIFTH AFFIRMATIVE DEFENSE

6 To the extent Plaintiffs are seeking recovery for benefits entitled to be received or
 7 actually received from any other source for injuries alleged in the Complaint, such benefits are
 8 not recoverable in this action.

FORTY-SIXTH AFFIRMATIVE DEFENSE

11 Plaintiffs' claims are barred in whole or part because they have been filed in an improper
 12 venue.

FORTY-SEVENTH AFFIRMATIVE DEFENSE

15 Defendants made no warranties of any kind, express or implied, or any representations of
 16 any nature whatsoever to Decedent and/or Plaintiffs herein. If any such warranties were made,
 17 whether express or implied, which Defendants specifically deny, then Plaintiffs failed to give
 18 timely notice of any breach thereof.

FORTY-EIGHTH AFFIRMATIVE DEFENSE

21 To the extent Plaintiffs seek restitution on behalf of individuals who used the subject
 22 pharmaceutical products and suffered no damage or loss as a result thereof, restitution is
 23 unavailable as nothing has been taken from those individuals, who allegedly could have an
 24 equitable basis for restitution.

FORTY-NINTH AFFIRMATIVE DEFENSE

Plaintiffs' claims for restitution for products previously used are barred in whole or in part because Decedent received benefits from the subject pharmaceutical products and nothing was wrongfully taken from Decedent and/or Plaintiffs.

FIFTIETH AFFIRMATIVE DEFENSE

Defendants intend to rely upon such other affirmative defenses as may become available or apparent during the course of investigation, discovery, or trial, and reserve the right to amend the Answer to assert such other defenses to which they may be entitled.

PRAYER

WHEREFORE, Defendants pray for judgment as follows:

1. That Plaintiffs take nothing from Defendants by reason of the Complaint;
2. That the Complaint be dismissed;
3. That Defendants be awarded their costs for this lawsuit;
4. That the trier of fact determine what percentage of the combined fault or other liability of all persons whose fault or other liability proximately caused Plaintiffs' alleged injuries, losses or damages is attributable to each person;
5. That any judgment for damages against Defendants in favor of Plaintiffs be no greater than an amount which equals their proportionate share, if any, of the total fault or other liability which proximately caused Plaintiffs' injuries and damages; and
6. That Defendants have such other and further relief as the Court deems appropriate.

DATED: July 31, 2008

TUCKER ELLIS & WEST LLP

By: /S/ Peter E. Schnaitman
Peter E. Schnaitman
Attorneys for Defendants
MYLAN INC., MYLAN
PHARMACEUTICALS, INC. and UDL
LABORATORIES, INC.

1 **JURY DEMAND**

2 Defendants Mylan Inc., Mylan Pharmaceuticals, Inc. and UDL Laboratories, Inc., hereby
3 demand a trial by jury of all the facts and issues in this case pursuant to 38(b) of the Federal
4 Rules of Civil Procedure.

5
6 DATED: July 31, 2008

TUCKER ELLIS & WEST LLP

7
8 By: /S/ Peter E. Schnaitman
9 Peter E. Schnaitman
10 Attorneys for Defendants
11 MYLAN INC., MYLAN
PHARMACEUTICALS, INC. and UDL
LABORATORIES, INC.

12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

CERTIFICATE OF SERVICE

I, Maria Valdez, declare as follows:

I am employed with the law firm of Tucker Ellis & West LLP, whose address is 515 South Flower Street, Suite 4200, Los Angeles, California 90071-2223. I am over the age of eighteen years, and am not a party to the within action.

On July 31, 2008, I served the following: **ANSWER OF MYLAN, INC., MYLAN PHARMACEUTICALS, INC., AND UDL LABORATORIES, INC.'S TO PLAINTIFF'S COMPLAINT** on the interested parties in this action by:

X **ELECTRONICALLY VIA ECF** the above-entitled document to be served electronically through the United States District Court, Northern Division ECF website on July 31, 2008 addressed to all parties appearing on the Court's ECF service list. The file transmission was reported as complete and a copy of the "Filing Receipt" page will be maintained with the original document in our office.

X (FEDERAL): I declare that I am employed in the office of a member of the bar of this court at whose direction the service was made.

Executed at Los Angeles, California on July 31, 2008.

/S/ Maria Valdez
Maria Valdez